PMID- 31454702
OWN - NLM
STAT- MEDLINE
DCOM- 20200224
LR  - 20200224
IS  - 1532-0456 (Print)
IS  - 1532-0456 (Linking)
VI  - 226
DP  - 2019 Dec
TI  - Potential use of 13-mer peptides based on phospholipase and oligoarginine as 
      leishmanicidal agents.
PG  - 108612
LID - S1532-0456(19)30328-X [pii]
LID - 10.1016/j.cbpc.2019.108612 [doi]
AB  - Phospholipase A(2) toxins present in snake venoms interact with biological membranes 
      and serve as structural models for the design of small peptides with anticancer, 
      antibacterial and antiparasitic properties. Oligoarginine peptides are capable of 
      increasing cell membrane permeability (cell penetrating peptides), and for this 
      reason are interesting delivery systems for compounds of pharmacological interest. 
      Inspired by these two families of bioactive molecules, we have synthesized two 
      13-mer peptides as potential antileishmanial leads gaining insights into structural 
      features useful for the future design of more potent peptides. The peptides included 
      p-Acl, reproducing a natural segment of a Lys49 PLA(2) from Agkistrodon contortrix 
      laticinctus snake venom, and its p-AclR7 analogue where all seven lysine residues 
      were replaced by arginines. Both peptides were active against promastigote and 
      amastigote forms of Leishmania (L.) amazonensis and L. (L.) infantum, while 
      displaying low cytotoxicity for primary murine macrophages. Spectrofluorimetric 
      studies suggest that permeabilization of the parasite's cell membrane is the 
      probable mechanism of action of these biomolecules. Relevantly, the engineered 
      peptide p-AclR7 was more active in both life stages of Leishmania and induced higher 
      rates of ethidium bromide incorporation than its native template p-Acl. Taken 
      together, the results suggest that short peptides based on phospholipase toxins are 
      potential scaffolds for development of antileishmanial candidates. Moreover, 
      specific amino acid substitutions, such those herein employed, may enhance the 
      antiparasitic action of these cationic peptides, encouraging their future biomedical 
      applications.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Mendes, Bruno
AU  - Mendes B
AD  - Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de 
      Campinas (UNICAMP), Campinas, São Paulo, Brazil.
FAU - Almeida, José R
AU  - Almeida JR
AD  - Universidad Regional Amazónica Ikiam, Km 7 Via Muyuna, Tena, Napo, Ecuador.
FAU - Vale, Nuno
AU  - Vale N
AD  - Laboratório de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de 
      Farmácia da Universidade do Porto, Portugal; IPATIMUP/Instituto de Investigação e 
      Inovação em Saúde (i3S), Universidade do Porto, Portugal.
FAU - Gomes, Paula
AU  - Gomes P
AD  - LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, 
      Universidade do Porto, Portugal.
FAU - Gadelha, Fernanda R
AU  - Gadelha FR
AD  - Departamento de Bioquímica e Biologia Tecidual, Instituto de Biologia, Universidade 
      Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil.
FAU - Da Silva, Saulo L
AU  - Da Silva SL
AD  - Facultad de Ciencias Químicas, Universidad de Cuenca, Cuenca/Azuay, Ecuador.; Centro 
      de Innovación de la Salud - EUS/EP, Cuenca/Azuay, Ecuador.
FAU - Miguel, Danilo C
AU  - Miguel DC
AD  - Departamento de Biologia Animal, Instituto de Biologia, Universidade Estadual de 
      Campinas (UNICAMP), Campinas, São Paulo, Brazil. Electronic address: 
      dcmiguel@unicamp.br.
LA  - eng
PT  - Journal Article
DEP - 20190824
PL  - United States
TA  - Comp Biochem Physiol C Toxicol Pharmacol
JT  - Comparative biochemistry and physiology. Toxicology & pharmacology : CBP
JID - 100959500
RN  - 0 (Crotalid Venoms)
RN  - 0 (Peptides)
RN  - EC 3.1.1.4 (Phospholipases A2)
SB  - IM
MH  - Agkistrodon/metabolism
MH  - Animals
MH  - Cells, Cultured
MH  - Crotalid Venoms/chemical synthesis/*pharmacology
MH  - Leishmania infantum/*drug effects
MH  - Leishmaniasis, Visceral/*drug therapy
MH  - Macrophages/cytology/*drug effects
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Peptides/chemical synthesis/*pharmacology
MH  - Phospholipases A2/*pharmacology
OTO - NOTNLM
OT  - Leishmanicidal activity
OT  - Oligoarginine
OT  - Peptide
OT  - Phospholipase
EDAT- 2019/08/28 06:00
MHDA- 2020/02/25 06:00
CRDT- 2019/08/28 06:00
PHST- 2019/07/19 00:00 [received]
PHST- 2019/08/21 00:00 [revised]
PHST- 2019/08/22 00:00 [accepted]
PHST- 2019/08/28 06:00 [pubmed]
PHST- 2020/02/25 06:00 [medline]
PHST- 2019/08/28 06:00 [entrez]
AID - S1532-0456(19)30328-X [pii]
AID - 10.1016/j.cbpc.2019.108612 [doi]
PST - ppublish
SO  - Comp Biochem Physiol C Toxicol Pharmacol. 2019 Dec;226:108612. doi: 
      10.1016/j.cbpc.2019.108612. Epub 2019 Aug 24.
